EFPIA's Roadmap of Priorities

EFPIA supports a vision of modern and sustainable healthcare systems in Europe, where patients have equal and early access to the best and safest medicines, which supports innovation, empowers citizens to make informed decisions about their health and ensures the highest security of the medicines supply chain. To turn this vision into reality, industry's efforts are focused around four key areas - the AIMS (Access, Innovation, Mobilization, Security) programme:

Access: "Patients must get products they need when they need them!"

Access refers to the need to continue to work towards speeding up regulatory approval and reimbursement processes for new medicines - removing government controls on medicines that are not reimbursed (G10 Recommendation 6) and ensure that Health Technology Assessment (HTA) does not become a fourth hurdle to market access.

Innovation: "Developing new medicines for the benefit of the patient"

Innovation focuses on efforts towards creating a strong science base in Europe and making Europe an attractive location for the best researchers - ensuring a fair reward for innovation, including incremental innovation and ensuring a high level of protection for Intellectual Property Rights.

Mobilization: "Informed patients are healthier patients"

Mobilization is about joining forces with key stakeholders to address the challenges of an ageing population and deliver modern and sustainable healthcare - to fight damaging cost-containment policies - to empower patients and citizens to take an active role in managing their health through better access to information from multiple sources - to highlight industry's contribution to access to medicines and to promote new incentives for research into diseases affecting the developing world.

Security: "Protect patients from counterfeit medicines"

Security refers to the need to strenghten the integrity and transparency of the pharmaceutical supply chain by addressing the safety concerns of parallel trade - raising public awareness on the risk of counterfeits and increasing the traceability of pharmaceutical products.